CTI BioPharma Corp (NASDAQ:CTIC) announced that the United Kingdom’s National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group has chosen to advance tosedostat, …
CTI BioPharma Corp (NASDAQ:CTIC) announced the initiation of its rolling new drug application (NDA) to the U.S.
CTI BioPharma Corp (NASDAQ:CTIC) announced that data highlighting two compounds (pacritinib and tosedostat) from the company’s investigational pipeline will be presented at the upcoming …
CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the third quarter ended September 30, 2015. “We are focused on preparing our NDA submission …
CTI BioPharma Corp (NASDAQ:CTIC) announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-1 Preferred …
CTI BioPharma Corp (NASDAQ:CTIC) and Fred Hutchinson Cancer Research Center (Fred Hutch) announced the establishment of a new $1.5 million research endowment fund – …
CTI BioPharma Corp (NASDAQ:CTIC) nnounced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company’s common …
CTI BioPharma Corp (NASDAQ:CTIC) announced its plan to submit a new drug application (NDA) to the U.S.
Roth Capital analyst Debjit Chattopadhyay weighed in with a few insights on CTI BioPharma Corp (NASDAQ:CTIC), after the company reported its second-quarter results and outlined its …
CTI BioPharma Corp (NASDAQ:CTIC) reported financial results for the second quarter ended June 30, 2015. “The significant interest from the oncology community generated …
